Suprachoroidal versus Intravitreal Triamcinolone Acetonide for the Treatment of Diabetic Macular Edema

References

• Saeedi O, Petersohn I, Salpea P, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation, Diabetes Atlas, 9th edition. Diabetes Res Clin Pract. 2019;157:107843. doi:10.1016/j.diabres.2019.107843
   PubMed Web of Science ®Google Scholar
• Wu L, Fernandez-Loaiza P, Sauma J, Hernandez-Bogantes E, Masis M. Classification of diabetic retinopathy and diabetic macular edema. World J Diabetes. 2013;4(6):290–294. doi:10.4239/wjd.v4.i6.290
   PubMedGoogle Scholar
• Bandello F, Parodi MB, Lanzetta P, et al. Diabetic macular edema. Dev Ophthalmol. 2017;58:102–138.
   PubMedGoogle Scholar
• Early Treatment Diabetic Retinopathy Study Research Group. Treatment techniques and clinical guidelines for photocoagulation of diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 2. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology. 1987;94:761–764. doi:10.1016/s0161-6420(87)33527-4
   PubMed Web of Science ®Google Scholar
• Park YG, Kim EY, Roh YJ. Laser-based strategies to treat diabetic macular edema: history and new promising therapies. J Ophthalmol. 2014;2014:1–9. doi:10.1155/2014/769213
   Web of Science ®Google Scholar
• Lanzetta P, Veritti D. The role of steroids in the treatment of diabetic macular edema. Retina Today. 2009;4:41–44.
   Google Scholar
• Zur D, Iglicki M, Loewenstein A. The role of steroids in the management of diabetic macular edema. Ophthalmic Res. 2019;62(4):231–236. doi:10.1159/000499540
   PubMed Web of Science ®Google Scholar
• Sharma T. Evolving role of anti-VEGF for diabetic macular oedema: from clinical trials to real life. Eye. 2020;34(3):415–417. doi:10.1038/s41433-019-0590-0
   PubMed Web of Science ®Google Scholar
• Bandello F, Zucchiatti I, Lattanzio R, Preziosa C. Diabetic macular edema. In: Bandello F, Zarbin MA, Lattanzio R, Zucchiatti I, editors. Clinical Strategies in the Management of Diabetic Retinopathy. A Step-By-Step Guide for Ophthalmologists. Heidelberg, Germany: Springer; 2014:65–122.
   Google Scholar
• Yamada N, Olsen TW. Routes for drug delivery to the retina: topical, transscleral, suprachoroidal and intravitreal gas phase delivery. Dev Ophthalmol. 2016;55:71–83.
   PubMedGoogle Scholar
• Chen M, Li X, Liu J, Han Y, Cheng L. Safety and pharmacodynamics of suprachoroidal injection of triamcinolone acetonide as a controlled ocular drug release model. J Control Release. 2015;203:109–117. doi:10.1016/j.jconrel.2015.02.021
   PubMed Web of Science ®Google Scholar
• Edelhauser HF, Verhoeven RS, Burke B, Struble CB, Patel SR. Intraocular distribution and targeting of triamcinolone acetonide suspension administered into the suprachoroidal space. Invest Ophthalmol Vis Sci. 2014;55:52–59.
   Web of Science ®Google Scholar
• Tyagi P, Kadam RS, Kompella UB. Comparison of suprachoroidal drug delivery with subconjunctival and intravitreal routes using noninvasive fluorophotometry. PLoS One. 2012;7(10):e48188. doi:10.1371/journal.pone.0048188
   PubMed Web of Science ®Google Scholar
• Yeh S, Kurup SK, Wang RC, et al.; for DOGWOOD Study Team. Suprachoroidal injection of Triamcinolone acetonide, CLS-TA, for macular edema due to noninfectious uveitis: a randomized, Phase 2 study (DOGWOOD). Retina. 2019;39(10):1880–1888. doi:10.1097/IAE.0000000000002279
   PubMed Web of Science ®Google Scholar
• Yeh S, Khurana RN, Shah M, et al.; for the PEACHTREE Study Investigators. Efficacy and safety of suprachoroidal CLS-TA for macular edema secondary to noninfectious uveitis: Phase 3 randomized trial. Ophthalmology. 2020;127(7):948–955. doi:10.1016/j.ophtha.2020.01.006
   PubMed Web of Science ®Google Scholar
• Campochiaro PA, Wykoff CC, Brown DM, et al.; for the Tanzanite Study Group. Suprachoroidal triamcinolone acetonide for retinal vein occlusion: results of the Tanzanite study. Ophthalmol Retina. 2017;2(4):320–328. doi:10.1016/j.oret.2017.07.013
   PubMedGoogle Scholar
• Barakat MR, Wykoff CC, Gonzalez V, et al. Suprachoroidal CLS-TA plus intravitreal aflibercept for diabetic macular edema: a randomized, double-masked, parallel-design, controlled study. Ophthalmol Retina. 2021;5(1):60–70. doi:10.1016/j.oret.2020.08.007
   PubMedGoogle Scholar
• Habot-Wilner Z, Noronha G, Wykoff CC. Suprachoroidally injected pharmacological agents for the treatment of chorio-retinal diseases: a targeted approach. Acta Ophthalmol. 2019;97:460–472. doi:10.1111/aos.14042
   PubMed Web of Science ®Google Scholar
• Wykoff CC, Khurana RN, Lampen SIR, et al. Suprachoroidal triamcinolone acetonide for diabetic macular edema: the HULK trial. Ophthalmol Retina. 2018;2:874–877. doi:10.1016/j.oret.2018.03.008
   PubMedGoogle Scholar
• Tayyab H, Ahmed CN, Sadiq MAA. Efficacy and safety of suprachoroidal triamcinolone acetonide in cases of resistant diabetic macular edema. Pak J Med Sci. 2020;36(2):42–47. doi:10.12669/pjms.36.2.1194
   PubMed Web of Science ®Google Scholar
• Yousef MS, Abd Elhafez YA, Farag MH. Assessment of suprachoroidal injection of triamcinolone acetonide in cases of diabetic macular edema. Int J Med Arts. 2021;3(2):1384–1389. doi:10.21608/ijma.2021.55079.1230
   Google Scholar
• Massin P, Audren F, Haouchine B, et al. Intravitreal triamcinolone acetonide for diabetic diffuse macular edema: preliminary results of a prospective controlled trial. Ophthalmology. 2004;111(2):218–224. doi:10.1016/j.ophtha.2003.05.037
   PubMed Web of Science ®Google Scholar
• Audren F, Lecleire-Collet A, Erginay A, et al. Intravitreal triamcinolone acetonide for diffuse diabetic macular edema: phase 2 trial comparing 4 mg vs 2 mg. Am J Ophthalmol. 2006;142(5):794–799. doi:10.1016/j.ajo.2006.06.011
   PubMed Web of Science ®Google Scholar